Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as 7-Valent Pneumococcal Conjugate Vaccine (7vPnC), 7-valent pneumococcal conjugate vaccine (vaccine), 7vPnC
7-valent pneumococcal conjugate vaccine · 3 trials · 3 indications
Vaccine efficacy can be assessed by measuring the levels of antibodies to the specific types (or serotypes) of bacteria covered by the vaccine. IgG antibodies for the 7 pneumococcal serotypes in 7vPnC (4, 6B, 9V, 14, 18C, 19F, 23F) were assessed 30-50 days after the third dose of vaccine. Antibody levels were measured by standardized enzyme-linked immunosorbent assay (ELISA). The minimum level of antibodies required to confer protection has been defined as 0.15 ug/ml by the Northern California Kaiser Permanente (NCKP) study, and as 0.35 ug/ml by the World Health Organization (WHO).
| Arm | Type | Description |
|---|---|---|
| 7vPnC (3-, 4-, 5-, 12-Month) | ACTIVE_COMPARATOR | - |
| 13vPnC (3-, 4-, 5-, 12-Month) | EXPERIMENTAL | - |
| 13vPnC (2-, 4-, 6-, 12-Month) | EXPERIMENTAL | - |
| 13vPnC (3-, 5-, 12-Month) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| 7-valent Pneumococcal Conjugate Vaccine | BIOLOGICAL | suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively |
| 13-valent Pnumococcal Conjugate vaccine | BIOLOGICAL | suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively |
| 7-valent pneumococcal conjugate vaccine (vaccine) | BIOLOGICAL | - |
| 23-valent pneumococcal conjugate vaccine (vaccine) | BIOLOGICAL | - |
| Diptheria and tetanus toxoids and accelular pertussis vaccine (DTaP) | BIOLOGICAL | - |
Inclusion Criteria: 1. Aged 42 to 77 days (approximately 2 months) at the time of enrollment. 2. Healthy infant as determined by medical history, physical examination, and judgment of the investigator. Exclusion Criteria: 1. Previous vaccination with licensed or investigational pneumococcal vacci...
The 7-valent pneumococcal conjugate vaccine is a vaccine designed to prevent pneumococcal infection. It has also been studied in people with HIV infections. It is given to healthy infants and to adults, including those with HIV, to stimulate immune protection against pneumococcal disease.
The 7-valent pneumococcal conjugate vaccine is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the company associated with the clinical development program for this vaccine.
The 7-valent pneumococcal conjugate vaccine is in Phase 2 clinical development. It is an investigational vaccine and is not approved. The program includes completed Phase 1 and Phase 2 trials, with a total of 2,474 participants enrolled across its studies.
The 7-valent pneumococcal conjugate vaccine has been studied in completed trials including NCT00488826, a Phase 1 study in healthy infants, and NCT00148824, a Phase 2 study of antibody responses to pneumococcal vaccines among HIV-infected adults in France. A related Phase 3 study, NCT01692886, evaluated the 13-valent pneumococcal conjugate vaccine in healthy infants in China.
Yes, 7vPnC is an abbreviation for the 7-valent pneumococcal conjugate vaccine. Other common forms of the name include 7 valent pneumococcal conjugate vaccine and 7-Valent Pneumococcal Conjugate Vaccine (7vPnc). These all refer to the same vaccine.